EQS-News: CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Michael Brosnan as an independent director to the company's Supervisory Board.
- TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Michael Brosnan as an independent director to the company's Supervisory Board.
- Mr. Brosnan replaces Hans Christoph Tanner, who has been a member of CureVac’s Supervisory Board since 2015.
- “Michael is an excellent addition to the CureVac board.
- His global financial and audit experience will help manage financial stability as we move towards late-stage clinical development and commercialization,” said Jean Stéphenne, Chairman of CureVac’s Supervisory Board.